People are already seeking the experimental weight‑loss drug retatrutide despite the fact that the Food and Drug Administration has not approved it for any use.
What retatrutide is and why it draws attention
Retatrutide is a triple‑agonist medication that targets three hormone receptors—glucagon‑like peptide‑1 (GLP‑1), gastric inhibitory polypeptide (GIP) and glucagon (GCG). By contrast, Wegovy (semaglutide) activates only the GLP‑1 receptor, while Zepbound (tirzepatide) works on GLP‑1 and GIP. The additional receptor activity is thought to boost appetite suppression and slow digestion more strongly.
Phase‑three trials have shown participants losing an average of 28.7 % of their body weight after 68 weeks on the highest dose. For context, tirzepatide trials reported weight losses of 15 % to 22.5 % over 72 weeks, and semaglutide trials recorded 10 % to 15 % over 68 weeks.
These results have prompted the drug to be labeled a potential “next big thing” in obesity treatment, even though Eli Lilly has not yet submitted the data to the FDA.
How the drug is appearing on the market
Because retatrutide is not yet approved, it is not legally available through standard pharmacies. Nevertheless, some online vendors claim to sell the medication, often through compounding pharmacies that produce custom formulations. The FDA issued a press release in February warning that selling retatrutide—or the related experimental drug cagrilintide—is illegal under federal law. The agency has also sent warning letters to companies distributing these substances.
Related: Sleep Apnea Affects Women in Unique Ways
Compounding pharmacies operate in a gray area: they can create versions of approved drugs during shortages, but once a medication is not approved at all, their activity becomes unlawful. The FDA’s drug enforcement page outlines the legal framework for such compounds.
Medical community’s warning
Dr. Mir Ali, medical director of the MemorialCare Surgical Weight Loss Center, says retatrutide “is not really available” except through enrollment in a clinical trial. He adds that there is no timeline for market entry because the trial data have not yet been filed with regulators.
Compounded versions may differ in potency or purity, raising the risk of ineffective treatment or adverse effects. “The worst‑case scenario is that you’re getting something unsafe or ineffective,” Ali warned. He recommends obtaining any weight‑loss medication through a licensed prescriber who can ensure the product meets established standards.
For patients who do not respond to existing GLP‑1 drugs—roughly 17 % are considered “non‑responders”—the temptation to try an unapproved alternative is understandable. However, the medical community stresses that alternative strategies, including different FDA‑approved medications, lifestyle changes, and specialist consultation, remain the safest path.
In practice, the promise of rapid weight loss can feel like a shortcut, but the reality is that unregulated drugs may bring unknown side effects, variable dosing, and a lack of long‑term safety data. Patients should weigh the allure of a dramatic percentage drop against the certainty of a vetted treatment plan.
Related: GLP-1 drug costs rise sharply
What patients can do now
Doctors advise individuals struggling with weight loss to discuss options with a healthcare provider experienced in obesity management.
Switching to another approved medication, adjusting dosage, or combining pharmacotherapy with nutrition and exercise counseling can improve outcomes. Both Ali and other experts emphasize that weight‑loss drugs work best when paired with a full lifestyle plan that includes self‑monitoring, balanced nutrition and both aerobic and resistance training.
Patients who consider enrolling in a clinical trial for retatrutide should confirm the study’s legitimacy through official registries and understand the trial’s protocol before participation.
Until retatrutide receives FDA clearance, the safest approach remains to use approved therapies under medical supervision and to avoid purchasing unverified versions online.
